<prof_article_slide_presentation>
  <front_label>Front Matter</front_label>
  <above_title>
    <p>
      <a href="/sites/advances/evolving-anticoagulation">Evolving Anticoagulation in AF and VTE</a>
    </p>
  </above_title>
  <title>
    <p>Extraordinary Cases of VTE Prevention in Patient with Cancer</p>
  </title>
  <contrbtr_pre_content>
    <p>As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest.  The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.</p>
<p>Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.</p>
  </contrbtr_pre_content>
  <contrbtr_byline>
    <p>Mark A. Crowther, MD; Lord Ajay K. Kakkar, MD, PhD, FRCS, FRCP</p>
  </contrbtr_byline>
  <contrbtr_group>
    <contrbtr_type_lbl>Faculty</contrbtr_type_lbl>
    <contrbtr_element chronicleid="0901c791807f56e9">
      <contrbtr_nm>Mark A. Crowther, MD</contrbtr_nm>
      <contrbtr_title>
        <p>Professor<br/>Chair<br/>Department of Medicine<br/>McMaster University<br/>Hamilton, Ontario, Canada</p>
      </contrbtr_title>
      <contrbtr_bio/>
      <contrbtr_disclsr>
        <p>Disclosure: Mark A. Crowther, MD, has disclosed the following relevant financial relationships:<br/>Served as an advisor or consultant for: Bristol-Myers Squibb Company Canada; Octapharma; Shionogi &amp; Co., Ltd.<br/>Received grants for clinical research from: Bayer HealthCare; LEO Pharma<br/>Owns stock, stock options, or bonds from: Alnylam Pharmaceuticals, Inc<br/>Other: Data safety monitoring board for: Bayer HealthCare; Daiichi Sankyo, Inc.; Preparation of Educational Materials and/or presentations for: Alexion Pharmaceuticals, Inc.; CSL Behring; Pfizer Inc.<br/>
          <br/>Dr Crowther does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.<br/>
          <br/>Dr Crowther does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>
      </contrbtr_disclsr>
    </contrbtr_element>
    <contrbtr_element chronicleid="0901c7918006a6c3">
      <contrbtr_nm>Lord Ajay K. Kakkar, MD, PhD, FRCS, FRCP</contrbtr_nm>
      <contrbtr_title>
        <p>Professor of Surgery<br/>University College London<br/>London, United Kingdom</p>
      </contrbtr_title>
      <contrbtr_bio/>
      <contrbtr_disclsr>
        <p>Disclosure: Lord Ajay K. Kakkar, MD, PhD, FRCS, FRCP, has disclosed the following relevant financial relationships:<br/>Served as an advisor or consultant for: AG Pharma; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Sanofi; Verseon<br/>Received grants for clinical research from: Bayer HealthCare<br/>
          <br/>Dr Kakkar does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.<br/>
          <br/>Dr Kakkar does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>
      </contrbtr_disclsr>
    </contrbtr_element>
  </contrbtr_group>
  <contrbtr_group>
    <contrbtr_type_lbl>Editor</contrbtr_type_lbl>
    <contrbtr_element>
      <contrbtr_nm>George Boutsalis, PhD</contrbtr_nm>
      <contrbtr_title>
        <p>Scientific Director, Medscape, LLC</p>
      </contrbtr_title>
      <contrbtr_bio/>
      <contrbtr_disclsr>
        <p>Disclosure: George Boutsalis has disclosed no relevant financial relationships.</p>
      </contrbtr_disclsr>
    </contrbtr_element>
  </contrbtr_group>
  <contrbtr_bulk_info/>
  <contrbtr_post_content>
    <p>
      <strong>Peer Reviewer</strong>
    </p>
<p>This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:<br/>Served as an advisor or consultant for: Abbott Laboratories; HeartWare International, Inc.; Medtronic, Inc.; Thoratec Corporation</p>
  </contrbtr_post_content>
  <supprtr_grant_group>
    <supprtr_grant_attr>/webmd/professional_assets/medscape/images/grant_attribution/daiichi-global-ieg-txt-2014.gif</supprtr_grant_attr>
  </supprtr_grant_group>
  <body_label>Body</body_label>
  <toc_element>
    <toc_label/>
    <toc_type>Default</toc_type>
    <sec_element>
      <sec_header/>
      <subsec_element>
        <subsec_header/>
        <slide_intro/>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide1.png</sec_img>
          <sec_label>Slide 1.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Extraordinary Cases of VTE Prevention in Patients With Cancer</h3>
          </sec_txt>
          <sec_alt_txt>Slide 1.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide2.png</sec_img>
          <sec_label>Slide 2.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Patient Case</h3>
          </sec_txt>
          <sec_alt_txt>Slide 2.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide3.png</sec_img>
          <sec_label>Slide 3.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Risks of Cancer-Associated PE</h3>
          </sec_txt>
          <sec_alt_txt>Slide 3.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide4.png</sec_img>
          <sec_label>Slide 4.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>CLOT: A Landmark Study for Treatment of Cancer-Associated Thrombosis<sup type="ref">[1]</sup>
              </h3>
              <ul>
              <li>    Despite the demonstrated value of low molecular weight heparin (LMWH) in reducing the risk of recurrent venous thromboembolism (VTE) in patients with cancer, many patients are reluctant to inject themselves daily, which presents an opportunity for the use of non-vitamin K antagonist oral anticoagulants (NOACs) and a greater chance for adherence to anticoagulant treatment </li>
            </ul>
          </sec_txt>
          <sec_alt_txt>Slide 4.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide5.png</sec_img>
          <sec_label>Slide 5.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Hokusai-VTE Cancer: Study Design<sup type="ref">[2,3]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 5.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide6.png</sec_img>
          <sec_label>Slide 6.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Hokusai VTE-Cancer: Primary Endpoint<sup type="ref">[2]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 6.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide7.png</sec_img>
          <sec_label>Slide 7.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Risk of Recurrent VTE in Cancer<sup type="ref">[4]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 7.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide8.png</sec_img>
          <sec_label>Slide 8.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>SELECT-D: Study Design<sup type="ref">[5]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 8.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide9.png</sec_img>
          <sec_label>Slide 9.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>SELECT-D: Efficacy and Safety<sup type="ref">[5]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 9.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide10.png</sec_img>
          <sec_label>Slide 10.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Dose Reduction in NOAC Trials<sup type="ref">[6-9]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 10.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide11.png</sec_img>
          <sec_label>Slide 11.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Clinical Implications of Hokusai VTE-Cancer and SELECT-D<sup type="ref">[2,5]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 11.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide12.png</sec_img>
          <sec_label>Slide 12.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Sites of Major Bleeding<sup type="ref">[2,5]</sup>
              </h3>
            <ul>
              <li>    <strong>Dr Kakkar:</strong> In a patient with pancreatic malignancy
              <ul>
                <li>    If the tumor is in the head of pancreases eroding into the duodenum, it is likely affecting the mucosa and associated with a potentially higher risk for bleeding</li>
                <li>    If the tumor is firmly confined in the head of pancreas, with no duodenal infringement, it is likely not associated with a higher risk for gastrointestinal (GI) bleeding</li>
              </ul>
              </li>
            </ul>
          </sec_txt>
          <sec_alt_txt>Slide 12.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide13.png</sec_img>
          <sec_label>Slide 13.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Use of NOACs in Cancer-Associated VTE: Considerations for GI Tract</h3>
            <ul>
              <li>    <strong>Dr Crowther:</strong> One of the experiences I have had in this area, is that some patients have a very strong preference for not self-injecting, and other patients think that self-injection implies that the treatment is more powerful -- it is important when talking with patients to have a discussion about which is the optimal therapy</li>
            </ul>
          </sec_txt>
          <sec_alt_txt>Slide 13.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide14.png</sec_img>
          <sec_label>Slide 14.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>US Prescription Patterns for Cancer-Associated VTE<sup type="ref">[10]</sup>
              </h3>
          </sec_txt>
          <sec_alt_txt>Slide 14.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide15.png</sec_img>
          <sec_label>Slide 15.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Cost Considerations for VTE prevention</h3>
          </sec_txt>
          <sec_alt_txt>Slide 15.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide16.png</sec_img>
          <sec_label>Slide 16.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Anticoagulation and Cancer Recurrence: Implications for Surgical interventions</h3>
          </sec_txt>
          <sec_alt_txt>Slide 16.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
        <slide_grp>
          <sec_img>/webmd/professional_assets/medscape/images/content/article/900/295/Slide17.png</sec_img>
          <sec_label>Slide 17.</sec_label>
          <sec_caption/>
          <sec_txt>
            <h3>Thank You</h3>
          </sec_txt>
          <sec_alt_txt>Slide 17.</sec_alt_txt>
          <qna_form/>
        </slide_grp>
      </subsec_element>
    </sec_element>
    <pg_footnotes/>
  </toc_element>
  <toc_element>
    <toc_label>
      <p>Abbreviations</p>
    </toc_label>
    <toc_type>Sidebar</toc_type>
    <sec_element>
      <sec_header>
        <p>Abbreviations</p>
      </sec_header>
      <subsec_element>
        <subsec_header/>
        <slide_intro>
          <p>bid = twice daily<br/>CrCl = creatinine clearance<br/>CRNMB = clinically relevant nonmajor bleeding<br/>DVT = deep vein thrombosis<br/>ERCP = endoscopic retrograde cholangiopancreatography<br/>GI = gastrointestinal<br/>IV = intravenous<br/>LMWH = low molecular weight heparin<br/>NOAC = non-vitamin K antagonist oral anticoagulant<br/>od = once daily<br/>PE = pulmonary embolism<br/>VKA = vitamin K antagonist<br/>VTE = venous thromboembolism</p>
        </slide_intro>
      </subsec_element>
    </sec_element>
    <pg_footnotes/>
  </toc_element>
  <toc_element>
    <toc_label/>
    <toc_type>References</toc_type>
    <sec_element>
      <sec_header/>
      <subsec_element>
        <subsec_header/>
        <slide_intro>
          <ol>
    <li>Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. <em>N Engl J Med. </em>2003;349:146-153.</li>
    <li>Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. <em>N Engl J Med. </em>2018;378:615-624.</li>
    <li>van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. <em>Thromb Haemost. </em>2015;114:1268-1276.</li>
    <li>van der Hulle T, den Exter PL, Planquette B, et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. <em>J Thromb Haemost. </em>2016;14:105-113.</li>
    <li>Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). <em>J Clin Oncol. </em>2018;36:2017-2023.</li>
    <li>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. <em>N Engl J Med. </em>2009;361:1139-1151.</li>
    <li>Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <em>N Engl J Med. </em>2011;365:883-891.</li>
    <li>Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. <em>N Engl J Med. </em>2011;365:981-992.</li>
    <li>Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. <em>The New England Journal of Medicine. </em>2013;369:2093-2104.</li>
    <li>Khorana AA, Yannicelli D, McCrae KR, et al. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? <em>Thromb Res. </em>2016;145:51-53.</li>
</ol>
        </slide_intro>
      </subsec_element>
    </sec_element>
    <pg_footnotes/>
  </toc_element>
  <back_label>Back Matter</back_label>
  <ref_grp>
    <ref_item/>
  </ref_grp>
  <cpyrt_holder>
    <p>Medscape, LLC</p>
  </cpyrt_holder>
  <cpyrt_ovrd/>
  <disclmr_ovrd/>
  <bkmtr_front>
    <p>
<strong>Disclaimer</strong>
</p>
<p>The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.</p>
<p>The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.</p>
  </bkmtr_front>
  <bkmtr_glossary/>
  <bkmtr_ack/>
  <bkmtr_discl/>
  <bkmtr_funding/>
  <bkmtr_reprnt_addr/>
  <bkmtr_abbr_notes/>
  <bkmtr_last/>
  <img_ttl_bkgrd>/webmd/professional_assets/medscape/images/title_background/banner-evolving-anticoagulation-2017.jpg</img_ttl_bkgrd>
  <img_publ_logo/>
</prof_article_slide_presentation>
